Core Viewpoint - Guichuang Tongqiao (02190.HK) announced the acquisition of 49% stake in German medical device company Optimed for €18.375 million, aiming to enhance its global market presence and accelerate product innovation [3][4]. Group 1: Acquisition Details - The acquisition allows Guichuang Tongqiao to hold an option for future acquisition of the remaining stake in Optimed [4]. - Optimed, established in 1996, specializes in the R&D, production, and global sales of minimally invasive vascular and urological intervention medical devices, with a sales network covering over 70 countries [4]. Group 2: Financial Performance - Guichuang Tongqiao achieved its first profit in 2024 and reported a profit of 121 million yuan in the first half of 2025, driven by the implementation of high-value medical consumables procurement policies in China [4]. - In the first half of 2025, the company generated revenue of 482 million yuan, with international business contributing 15.7 million yuan, marking a 36.9% year-on-year increase, primarily from Europe and Asia [5]. Group 3: Global Strategy - The company emphasizes a global strategy as a key focus for development, identifying significant growth potential in the overseas intervention consumables market, particularly in Europe and emerging markets [5]. - Challenges in entering overseas markets include brand building and channel development, which the acquisition aims to address by strengthening the company's overseas channel layout [5].
补强欧洲销售渠道，归创通桥收购德国介入耗材厂商